1110767-89-9

Basic information

• Product Name: (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid
• Synonyms: (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid;(E)-3,5-dichloro-4-(3-methoxy-2-methyl-3-oxoprop-1-en-1-yl)benzoic acid;3,5-Dichloro-4-[(1E)-3-ethoxy-2-methyl-3-oxo-1-propen-1-yl]benzoic acid;3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid
• CAS NO: 1110767-89-9
• Molecular Formula: C₁₃H₁₂Cl₂O₄
• Molecular Weight: 303.13798
• EINECS: -0
• Mol File: 1110767-89-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 442.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.380±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.43±0.10(Predicted)
• CAS DataBase Reference: (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid(1110767-89-9)
• EPA Substance Registry System: (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop-1-enyl)benzoic acid(1110767-89-9)

Safety Data

• Hazardous Substances Data: 1110767-89-9(Hazardous Substances Data)

Usage

Uses

(E)?-?3,?5-?Dichloro-?4-?(3-?ethoxy-?2-?methyl-?3-?oxoprop-?1-?en-?1-?yl)?benzoic Acid is an intermiediate of Lusutrombopag (L474985), a newly discovered thrombopoietin receptor agonist used in the treatment of patients with chronic ITP.

Upstream product

• 4394-85-8 4-morpholinecarboxaldehyde 
• 3699-66-9 ethyl 2-diethoxyphosphorylpropionate 
• 51-36-5 3,5-dichlorobenzoic acid 
• 153203-80-6 3,5-dichloro-4-formylbenzoic acid 

Downstream Products

• 1110767-87-7 ethyl (S)-(E)-3-(2,6-dichloro-4-{4-[2-methyloxy-3-(1-methyloxyheptyl)phenyl]thiazol-2-ylcarbamoyl}phenyl)-2-methylacrylate 

Relevant articles and documents

Development of manufacturing processes for the carboxylic acid key intermediate of lusutrombopag: One-pot reaction process of formylation and the horner-wadsworth-emmons reaction

We describe the development of a one-pot preparation process of (E)-3,5-dichloro-4-(3-ethoxy-2-methyl-3-oxoprop- 1-en-1-yl)benzoic acid (3), which is a key carboxylic acid intermediate of lusutrombopag. This one-pot reaction process is composed of lithiation of 3,5-dichlorobenzoic acid with lithium diisopropylamide (LDA), formylation using N-formylmorpholine, followed by olefination employing the Horner-Wadsworth-Emmons reaction with triethyl 2-phosphonopropionate. This method enabled kilogram-scale manufacturing of carboxylic acid 3, a key intermediate of lusutrombopag with high purity, together with a reduced number of steps, improvement of yield, and avoidance of a cumbersome procedure for isolation of the intermediate.